Search

Your search keyword '"Swinnen, Lode J."' showing total 226 results
Start Over Author "Swinnen, Lode J." Publication Type Academic Journals
226 results on '"Swinnen, Lode J."'

3. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

Author

Imus, Philip H., Tsai, Hua-Ling, DeZern, Amy E., Jerde, Kevin, Swinnen, Lode J., Bolaños-Meade, Javier, Luznik, Leo, Fuchs, Ephraim J., Wagner-Johnston, Nina, Huff, Carol Ann, Gladstone, Douglas E., Ambinder, Richard F., Gocke, Christian B., Ali, Syed Abbas, Borrello, Ivan M., Varadhan, Ravi, Brodsky, Robert, and Jones, Richard J.

Published
2020
Full Text
View/download PDF

4. Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide

Author

DeZern, Amy E., Elmariah, Hany, Zahurak, Marianna, Rosner, Gary L., Gladstone, Douglas E., Ali, Syed Abbas, Huff, Carol Ann, Swinnen, Lode J., Imus, Phil, Borrello, Ivan, Wagner-Johnston, Nina D., Ambinder, Richard F., Brodsky, Robert A., Cooke, Kenneth, Luznik, Leo, Fuchs, Ephraim J., Bolaños-Meade, Javier, and Jones, Richard J.

Published
2020
Full Text
View/download PDF

7. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source

Author

Sterling, Cole H., Hughes, Michael S., Tsai, Hua-Ling, Yarkony, Kathryn, Fuchs, Ephraim J., Swinnen, Lode J., Paul, Suman, Bolaños-Meade, Javier, Luznik, Leo, Imus, Philip H., Ali, Syed Abbas, Jain, Tania, Ambinder, Alexander, DeZern, Amy, Huff, Carol Ann, Gocke, Christian B., Varadhan, Ravi, Wagner-Johnston, Nina, Jones, Richard J., and Ambinder, Richard F.

Published
2023
Full Text
View/download PDF

8. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

Author

Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Habermann, Thomas M, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Wilson, Lynn, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, and Sundar, Hema

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Orphan Drug, Hematology, Clinical Research, Rare Diseases, Lymphoma, Cancer, Algorithms, Comorbidity, Disease Management, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm Staging, Prognosis, National comprehension cancer network, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.

Published
2015

11. Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide

Author

McCurdy, Shannon R., Kanakry, Christopher G., Tsai, Hua-Ling, Gojo, Ivana, Smith, B. Douglas, Gladstone, Douglas E., Bolaños-Meade, Javier, Borrello, Ivan, Matsui, William H., Swinnen, Lode J., Huff, Carol Ann, Brodsky, Robert A., Ambinder, Richard F., Fuchs, Ephraim J., Rosner, Gary L., Jones, Richard J., and Luznik, Leo

Published
2019
Full Text
View/download PDF

12. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial

Author

Bolaños-Meade, Javier, Cooke, Kenneth R, Gamper, Christopher J, Ali, Syed Abbas, Ambinder, Richard F, Borrello, Ivan M, Fuchs, Ephraim J, Gladstone, Douglas E, Gocke, Christian B, Huff, Carol Ann, Luznik, Leo, Swinnen, Lode J, Symons, Heather J, Terezakis, Stephanie A, Wagner-Johnston, Nina, Jones, Richard J, and Brodsky, Robert A

Published
2019
Full Text
View/download PDF

13. Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.

Author

Nabors, Louis Burt, Portnow, Jana, Ammirati, Mario, Brem, Henry, Brown, Paul, Butowski, Nicholas, Chamberlain, Marc C, DeAngelis, Lisa M, Fenstermaker, Robert A, Friedman, Allan, Gilbert, Mark R, Hattangadi-Gluth, Jona, Hesser, Deneen, Holdhoff, Matthias, Junck, Larry, Lawson, Ronald, Loeffler, Jay S, Moots, Paul L, Mrugala, Maciej M, Newton, Herbert B, Raizer, Jeffrey J, Recht, Lawrence, Shonka, Nicole, Shrieve, Dennis C, Sills, Allen K, Swinnen, Lode J, Tran, David, Tran, Nam, Vrionis, Frank D, Wen, Patrick Yung, McMillian, Nicole R, and Ho, Maria

Subjects
Brain Cancer, Brain Disorders, Cancer, Neurosciences, Rare Diseases, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Neurological, Central Nervous System Neoplasms, Humans, Radiosurgery, Oncology & Carcinogenesis
Abstract

The NCCN Guidelines for Central Nervous System Cancers provide multidisciplinary recommendations for the clinical management of patients with cancers of the central nervous system. These NCCN Guidelines Insights highlight recent updates regarding the management of metastatic brain tumors using radiation therapy. Use of stereotactic radiosurgery (SRS) is no longer limited to patients with 3 or fewer lesions, because data suggest that total disease burden, rather than number of lesions, is predictive of survival benefits associated with the technique. SRS is increasingly becoming an integral part of management of patients with controlled, low-volume brain metastases.

Published
2014

14. Non-Hodgkin's lymphomas, version 4.2014.

Author

Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, and Sundar, Hema

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Hematology, Rare Diseases, Stem Cell Research, Lymphoma, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Humans, Lymphoma, Non-Hodgkin, Neoplasm Staging, Recurrence, National comprehensive cancer network, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

Published
2014

15. Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes

Author

McCurdy, Shannon R., Muth, Stephen T., Tsai, Hua-Ling, Symons, Heather J., Huff, Carol Ann, Matsui, William H., Borrello, Ivan, Gladstone, Douglas E., Swinnen, Lode J., Cooke, Kenneth R., Brodsky, Robert A., Bolaños-Meade, Javier, Ambinder, Richard F., Varadhan, Ravi, Luznik, Leo, Jones, Richard J., Bettinot, Maria P., and Fuchs, Ephraim J.

Published
2018
Full Text
View/download PDF

19. Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation

Author

Imus, Philip H., Blackford, Amanda L., Bettinotti, Maria, Iglehart, Brian, Dietrich, August, Tucker, Noah, Symons, Heather, Cooke, Kenneth R., Luznik, Leo, Fuchs, Ephraim J., Brodsky, Robert A., Matsui, William H., Huff, Carol Ann, Gladstone, Douglas, Ambinder, Richard F., Borrello, Ivan M., Swinnen, Lode J., Jones, Richard J., and Bolaños-Meade, Javier

Published
2017
Full Text
View/download PDF

21. Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide

Author

Rappazzo, Katherine C., Zahurak, Marianna, Bettinotti, Maria, Ali, Syed Abbas, Ambinder, Alex J., Bolaños-Meade, Javier, Borrello, Ivan, Dezern, Amy E., Gladstone, Doug, Gocke, Christian, Fuchs, Ephraim, Huff, Carol Ann, Imus, Philip H., Jain, Tania, Luznik, Leo, Rahmat, Leena, Swinnen, Lode J., Wagner-Johnston, Nina, Jones, Richard J., and Ambinder, Richard F.

Published
2021
Full Text
View/download PDF

22. Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma

Author

Sterling, Cole H., Tsai, Hua-Ling, Holdhoff, Matthias, Bolaños-Meade, Javier, Luznik, Leo, Fuchs, Ephraim J., Huff, Carol Ann, Gocke, Christian B., Ali, Syed Abbas, Borrello, Ivan M., Varadhan, Ravi, Jones, Richard J., Gladstone, Douglas E., Ambinder, Richard F., Wagner-Johnston, Nina, Swinnen, Lode J., and Imus, Philip H.

Published
2021
Full Text
View/download PDF

23. Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors

Author

Kanakry, Jennifer A., Gocke, Christopher D., Bolaños-Meade, Javier, Gladstone, Douglas E., Swinnen, Lode J., Blackford, Amanda L., Fuchs, Ephraim J., Huff, Carol Ann, Borrello, Ivan, Matsui, William H., Brodsky, Robert A., Rosner, Gary L., Shanbhag, Satish, Luznik, Leo, Jones, Richard J., Ambinder, Richard F., and Kasamon, Yvette L.

Published
2015
Full Text
View/download PDF

24. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Author

McCurdy, Shannon R., Kanakry, Jennifer A., Showel, Margaret M., Tsai, Hua-Ling, Bolaños-Meade, Javier, Rosner, Gary L., Kanakry, Christopher G., Perica, Karlo, Symons, Heather J., Brodsky, Robert A., Gladstone, Douglas E., Huff, Carol Ann, Pratz, Keith W., Prince, Gabrielle T., Dezern, Amy E., Gojo, Ivana, Matsui, William H., Borrello, Ivan, McDevitt, Michael A., Swinnen, Lode J., Smith, B. Douglas, Levis, Mark J., Ambinder, Richard F., Luznik, Leo, Jones, Richard J., Fuchs, Ephraim J., and Kasamon, Yvette L.

Published
2015
Full Text
View/download PDF

25. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Author

Kanakry, Christopher G., Tsai, Hua-Ling, Bolaños-Meade, Javier, Smith, B. Douglas, Gojo, Ivana, Kanakry, Jennifer A., Kasamon, Yvette L., Gladstone, Douglas E., Matsui, William, Borrello, Ivan, Huff, Carol Ann, Swinnen, Lode J., Powell, Jonathan D., Pratz, Keith W., DeZern, Amy E., Showel, Margaret M., McDevitt, Michael A., Brodsky, Robert A., Levis, Mark J., Ambinder, Richard F., Fuchs, Ephraim J., Rosner, Gary L., Jones, Richard J., and Luznik, Leo

Published
2014
Full Text
View/download PDF

26. Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Author

Webster, Jonathan Allen, Reed, Madison C., Tsai, Hua-Ling, Ambinder, Alexander J., Jain, Tania, DeZern, Amy E., Levis, Mark J., Showel, Margaret M., Prince, Gabrielle T., Hourigan, Christopher S., Bolaños-Meade, Javier, Gondek, Lukasz P., Ghiaur, Gabriel, Dalton, William Brian, Paul, Suman, Fuchs, Ephraim J., Gocke, Christian B., Ali, Abbas Abbas, Gladstone, Douglas E., Huff, Carol Ann, Borrello, Ivan M., Swinnen, Lode J., Wagner-Johnston, Nina D., Ambinder, Richard F., Luznik, Leo, Gojo, Ivana, Smith, B. Douglas Douglas, Varadhan, Ravi, Jones, Richard J., and Imus, Philip H.

Published
2022
Full Text
View/download PDF

28. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402

Author

Williams, Michael E., Hong, Fangxin, Gascoyne, Randy D., Wagner, Lynne I., Krauss, John C., Habermann, Thomas M., Swinnen, Lode J., Schuster, Stephen J., Peterson, Christopher G., Sborov, Mark D., Martin, Eric S., Weiss, Matthias, Ehmann, Christopher W., Horning, Sandra J., and Kahl, Brad S.

Published
2016
Full Text
View/download PDF

30. Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome

Author

Kasamon, Yvette L., Luznik, Leo, Leffell, Mary S., Kowalski, Jeanne, Tsai, Hua-Ling, Bolaños-Meade, Javier, Morris, Lawrence E., Crilley, Pamela A., O'Donnell, Paul V., Rossiter, Nancy, Huff, Carol Ann, Brodsky, Robert A., Matsui, William H., Swinnen, Lode J., Borrello, Ivan, Powell, Jonathan D., Ambinder, Richard F., Jones, Richard J., and Fuchs, Ephraim J.

Published
2010
Full Text
View/download PDF

33. Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study.

Author

Hughes, Michael S., Sterling, Cole H., Varadhan, Ravi, Ambinder, Richard F., Jones, Richard J., Sweren, Ronald J., Rozati, Sima, Bolaños-Meade, Javier, Luznik, Leo, Imus, Philip H., Ali, Syed Abbas, Borrello, Ivan M., Huff, Carol Ann, T., Jain, Ambinder, Alexander, DeZern, Amy E., Gocke, Christian B., Gladstone, Douglas E., Swinnen, Lode J., and Wagner-Johnston, Nina D.

Subjects
CUTANEOUS T-cell lymphoma, SEZARY syndrome, CORD blood transplantation, HEMATOPOIETIC stem cell transplantation
Abstract

Two individuals (patients 7 and 8) received immune checkpoint inhibition (ICI) prior to BMT; patient 7 received anti-CTLA-4 and anti-PD-1 combination therapy, and patient 8 received anti-PD-L1 and interferon combination therapy. From 2003 to 2020, eight patients received partially mismatched donor BMT for relapsed/refractory MF/SS. Seven patients received grafts from HLA-haploidentical related donors. Primary cutaneous T-cell lymphomas (CTCLs), a heterogeneous group of extranodal non-Hodgkin lymphomas involving the skin, are dominated by two main subtypes: mycosis fungoides (MF) and Sézary syndrome (SS) [[1]]. An eighth patient (patient 5) experienced graft failure after double unrelated donor umbilical cord blood transplantation and within 6 months underwent partially mismatched unrelated donor BMT. [Extracted from the article]

Published
2022
Full Text
View/download PDF

34. A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

Author

Webster, Jonathan Allen, Jones, Richard J., Blackford, Amanda, Shedeck, Audra, Ambinder, Richard F., Swinnen, Lode J., Wagner-Johnston, Nina, Fuchs, Ephraim Joseph, Bolanos-Meade, Javier, Imus, Philip, Bonifant, Challice L., Symons, Heather Jill, Jain, Tania, Prince, Gabrielle T., Levis, Mark J., Luznik, Leo, and Gojo, Ivana

Published
2023
Full Text
View/download PDF

35. Phase 2 Response-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, and Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Author

Simard, Jillian, Phelan, James D, Melani, Christopher, Lakhotia, Rahul, Pittaluga, Stefania, Muppidi, Jagan R., Lionakis, Michail, Peer, Cody J, Pradhan, Amynah, Holdhoff, Matthias, Swinnen, Lode J., Dunleavy, Kieron, Lai, Catherine, Ibrahimi, Sami, Glantz, Michael, Butman, John A, Johnson, Kim, Steinberg, Seth M., Figg, William, Jaffe, Elaine S., Staudt, Louis M., Wilson, Wyndham H., and Roschewski, Mark

Published
2023
Full Text
View/download PDF

36. Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Author

Webster, Jonathan, Tsai, Hua-Ling, Gehrie, Eric, Jain, Tania, Hourigan, Christopher S., Dalton, William Brian, Prince, Gabrielle T., Gondek, Lukasz P., Ghiaur, Gabriel, DeZern, Amy E., Showel, Margaret M., Gojo, Ivana, Gladstone, Douglas E, Imus, Philip H., Bolanos-Meade, Javier, Luznik, Leo, Fuchs, Ephraim J., Gocke, Christian B., Ali, Abbas Abbas, Huff, Carol Ann, Borrello, Ivan M., Swinnen, Lode J., Wagner-Johnston, Nina D., Ambinder, Richard F., Jones, Richard J., Smith, B. Douglas, and Levis, Mark

Published
2020
Full Text
View/download PDF

38. ABCL-187 Phase 2 Response-Adapted Study of Ibrutinib With Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Author

Simard, Jillian, Phelan, James D, Melani, Christopher, Lakhotia, Rahul, Pittaluga, Stefania, Muppidi, Jagan R, Lionakis, Michail S, Peer, Cody, Pradhan, Amynah, Holdhoff, Matthias, Swinnen, Lode J, Dunleavy, Kieron, Lai, Catherine, Ibrahimi, Sami, Glantz, Michael, Butman, John A, Johnson, Kim, Steinberg, Seth M, Figg, William D, Jaffe, Elaine S, Staudt, Louis M, Wilson, Wyndham H, and Roschewski, Mark

Published
2023
Full Text
View/download PDF

39. POSTER: ABCL-187 Phase 2 Response-Adapted Study of Ibrutinib With Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Author

Simard, Jillian, Phelan, James D, Melani, Christopher, Lakhotia, Rahul, Pittaluga, Stefania, Muppidi, Jagan R, Lionakis, Michail S, Peer, Cody, Pradhan, Amynah, Holdhoff, Matthias, Swinnen, Lode J, Dunleavy, Kieron, Lai, Catherine, Ibrahimi, Sami, Glantz, Michael, Butman, John A, Johnson, Kim, Steinberg, Seth M, Figg, William D, Jaffe, Elaine S, Staudt, Louis M, Wilson, Wyndham H, and Roschewski, Mark

Published
2023
Full Text
View/download PDF

40. Induction of Autologous Graft-versus-Host Disease: Results of a Randomized Prospective Clinical Trial in Patients with Poor Risk Lymphoma

Author

Bolaños-Meade, Javier, Garrett-Mayer, Elizabeth, Luznik, Leo, Anders, Viki, Webb, Jennifer, Fuchs, Ephraim J., Huff, Carol Ann, Matsui, William, Borrello, Ivan M., Brodsky, Robert, Kasamon, Yvette L., Swinnen, Lode J., Flinn, Ian W., Ambinder, Richard F., Jones, Richard J., Hess, Allan D., and Vogelsang, Georgia B.

Published
2007
Full Text
View/download PDF

41. An Open Label Trial of Sustained-release Cytarabine (DepoCyt™) for the Intrathecal Treatment of Solid Tumor Neoplastic Meningitis

Author

Jaeckle, Kurt A., Batchelor, Tracy, O'Day, Steven J., Phuphanich, Surasak, New, Pamela, Lesser, Glenn, Cohn, Allen, Gilbert, Mark, Aiken, Robert, Heros, Deborah, Rogers, Lisa, Wong, Eric, Fulton, Dorcas, Gutheil, John C., Baidas, Said, Kennedy, Julia M., Mason, Warren, Moots, Paul, Russell, Christy, Swinnen, Lode J., and Howell, Stephen B.

Published
2002
Full Text
View/download PDF

46. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non–First-Degree Related Donors

Author

Elmariah, Hany, Kasamon, Yvette L., Zahurak, Marianna, Macfarlane, Karen W., Tucker, Noah, Rosner, Gary L., Bolaños-Meade, Javier, Fuchs, Ephraim J., Wagner-Johnston, Nina, Swinnen, Lode J., Huff, Carol Ann, Matsui, William H., Gladstone, Douglas E., McCurdy, Shannon R., Borrello, Ivan, Gocke, Christian B., Shanbhag, Satish, Cooke, Kenneth R., Ali, Syed Abbas, Brodsky, Robert A., DeZern, Amy E., Luznik, Leo, Jones, Richard J., and Ambinder, Richard F.

Published
2018
Full Text
View/download PDF

49. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients

Author

Swinnen, Lode J., Costanzo-Nordin, Maria R., Fisher, Susan G., O'Sullivan, E. Jeanne, Johnson, Maryl R., Heroux, Alain L., Dizikes, George J., Pifarre, Roque, and Fisher, Richard I.

Subjects
Transplantation of organs, tissues, etc. -- Complications, Monoclonal antibodies -- Adverse and side effects, OKT3 -- Adverse and side effects, Immunosuppressive agents -- Adverse and side effects, Immunosuppression -- Complications, Lymphoproliferative disorders -- Causes of
Abstract

To a great degree, the success of organ transplantation procedures has resulted from improvements in methods of immunosuppression, which reduce the likelihood that the recipient's immune system will reject the new organ. However, this necessary immunosuppression is not without its own potential complications. Like the immunosuppression due to chemotherapy and that due to AIDS, the immunosuppression for transplantation may result in infection and lymphoproliferative disorder. The lymphoproliferative disorder, which can be life-threatening, is thought to result from primary or reactivated infection with the Epstein-Barr virus. An increase in the incidence of lymphoproliferative disorder was recently observed in a series of heart transplant patients at one institution. Researchers noticed that the increase seemed to occur at the same time that a new method of improving immunosuppression was introduced. A retrospective study of 154 heart-transplant patients was then undertaken to determine if this treatment was, indeed, responsible for the increase in lymphoproliferative disorder. The new treatment was the use of the drug OKT3 for immunosuppression. OKT3 is a monoclonal antibody which binds to the CD3 receptor on T cells. In humans, treatment with OKT3 results in a depletion of circulating T cells with the CD3-positive lymphocytes. Previously, OKT3 had been reserved as treatment for those cases in which conventional immunosuppression was failing, but recently it has come to be used prophylactically for all transplant patients at some medical centers. The review of the patient records revealed that post-transplantation lymphoproliferative disorders developed in 1 of 75 patients (1.3 percent) who did not receive OKT3, and in 9 of 79 patients (11.4 percent) who did get the monoclonal antibody. Statistical analysis showed that the OKT3 antibody was the only variable which was significantly associated with the development of lymphoproliferative disorder in these patients. Since the value of OKT3 as a prophylactic agent in transplant patients has not been clearly established, the risks must be carefully considered before the treatment is prescribed. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

50. Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Author

Kanakry, Christopher G., Bolaños-Meade, Javier, Kasamon, Yvette L., Zahurak, Marianna, Durakovic, Nadira, Furlong, Terry, Mielcarek, Marco, Medeot, Marta, Gojo, Ivana, Smith, B.Douglas, Kanakry, Jennifer A., Borrello, Ivan M., Brodsky, Robert A., Gladstone, Douglas E., Huff, Carol Ann, Matsui, William H., Swinnen, Lode J., Cooke, Kenneth R., Ambinder, Richard F., Fuchs, Ephraim J., de Lima, Marcos J., Andersson, Borje S., Varadhan, Ravi, O'Donnell, Paul V., Jones, Richard J., and Luznik, Leo

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results